CBD and CBG are cannabinoids that are studied and used today. Known for their benefits, they act as antioxidants and neuroprotective effects. A recently published Italian study confirms their action.
CBD, CBG, and neurological diseases
Cannabidiol (CBD) and cannabigerol (CBG) are terpene phenolics of Cannabis sativa. Although the efficacy of CBD against neurological diseases has already demonstrated, fewer studies have been able to address the action of CBG.
Therefore, a comparison of the effects of these compounds is performed in two experimental models mimicking oxidative stress and neurotoxicity occurring in neurological diseases.
This study has been conducted at the Department of Pharmacy, University of Chieti, Italy. You can consult it here.
Study: CBD & CBG antioxidants and neuroprotectants
Rat astrocytes exposed to hydrogen peroxide, and cell viability, production of reactive oxygen species, and the occurrence of apoptosis were studied.
The cortex was exposed to a K + 60 mM depolarizing stimulus, and serotonin (5-HT) turnover, 3-hydroxykynurenine, and kynurenic acid levels were measured. Proteomic analysis and bioinformatics and mooring studies conducted.
Both compounds exerted antioxidant effects in astrocytes and restored 5-HT cortex levels depleted by neurotoxic stimuli, while the single CBD restored basal levels of 3-hydroxykynurenine and kynurenic acid.
CBG was less effective than CBD in restoring the levels of proteins involved in neurotransmitter exocytosis. Mooring assays predicted the inhibitory effects of these compounds on the neurokinin B receptor.
Results in the in vitro system suggest that non-neuronal brain cells are a target for the treatment of oxidative conditions, whereas the results in the ex vivo system and docking assays imply the potential roles of CBD and CBG as neuroprotective agents.